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We address concerns raised in this issue by Bretzner et al. (2011) by explaining the rationale for including
subjects with subacute, neurologically complete spinal cord injuries in the Phase 1 trial of GRNOPC1.
We also present elements of the informed consent process that minimize the likelihood of therapeutic
misconception.In the article entitled, ‘‘Target Populations
for First-In-Human Embryonic Stem Cell
Research in Spinal Cord Injury,’’ Bretzner
et al. (2011) raise concerns regarding the
subacute spinal cord injury patient popu-
lation chosen for the first clinical trial
testing the safety of GRNOPC1. Bretzner
et al. also detail specific ethical consider-
ations in the selection of the patient pop-
ulation for this first-in-human clinical trial.
Our response is as follows.
Challenges by Bretzner et al.
to Testing GRNOPC1 in Subjects
with Subacute Complete SCI
Spontaneous Recovery of Subjects
with Complete Injuries
Bretzner et al. (2011) contend that there is
a significant problem with the chosen
target population, patients with subacute
complete SCI, as spontaneous recovery
that might otherwise occur could be
impaired by injection of GRNOPC1. The
Geron clinical protocol includes several
preinjection International Standards for
Neurological Classification of Spinal
Cord Injury (ISNCSCI) exams to ensure,
to the extent feasible, that all participants
are neurologically complete at the time of
GRNOPC1 injection. For example, the
protocol stipulates that the first study-
driven ISNCSCI exam must performed at
least 72 hr following the individual’s SCI.
This cutoff was derived from the paper
(Burns et al., 2003) cited by Bretzner
et al.; persons who are neurologically
complete at this stage have very little
chance of clinically meaningful sponta-
neous recovery, especially motor
recovery in the lower extremities. The clin-476 Cell Stem Cell 8, May 6, 2011 ª2011 Elsical protocol calls for an additional full
ISNCSCI exam at baseline (i.e., 2 days
prior to GRNOPC1 injection) and a rectal
exam the day prior to injection to recon-
firm absence of sensation and voluntary
contraction at sacral levels S4–S5. All
ISNCSCI exams are performed by exam-
iners who have been trained, evaluated,
and qualified by an independent company
that specializes in ISNCSCI training.
The Secondary Endpoint
Bretzner et al. express some concern that
efficacy is a secondary endpoint of the
clinical trial. It should be noted that
many of the neurological outcome
measures utilized in the trial to monitor
safety, e.g., the ISNCSCI exam, can also
be used tomonitor improvement in neuro-
logical function. It is in this context that
efficacy is a secondary endpoint. It should
be noted that comprehensive investiga-
tions to assess the efficacy of GRNOPC1
will only be included in advanced clinical
trials.
Preclinical Animal Models
Bretzner et al. also raise concern that
Geron’s preclinical studies were per-
formed in contused rats with incomplete
injuries while the clinical trial is being con-
ducted in subjects with complete injuries.
Typically, animal models that produce
neurologically complete injuries involve
complete transection of the spinal cord.
Based on the proposed mechanisms of
action for GRNOPC1, these cells would
not be expected to have positive impact
on such transection injuries. By contrast,
eligibility for the Geron trial is restricted
to those patients who exhibit a severity
and pattern of spinal cord tissue damageevier Inc.on the screening/baseline MRI scan that
is similar to contusion injuries used in the
preclinical safety and efficacy rat studies
of GRNOPC1. For example, patients are
excluded from the Geron trial if the
screening/baseline MRI exam shows any
of the following: anatomic transection,
significant cord laceration, or minimal
residual spinal cord tissue at the injury
epicenter.
Therapeutic Misconception
Bretzner et al. argue that the use of
subacute complete SCI patients in Ger-
on’s Phase I safety trial of hESC-derived
GRNOPC1 is inappropriate because
these patients are particularly vulnerable
and, therefore, may be subject to ‘‘thera-
peutic misconception.’’ Their argument
turns on questions of undue influence,
exploitation, and patient vulnerability.
Bretzner et al. define therapeutic
misconception as ‘‘conflating participa-
tion in a clinical trial with accessing novel
medical treatment(s).’’ We concur that
patients entering a clinical trial should
not confuse research with therapy. The
International Society for Stem Cell
Research highlights the importance of
minimizing misconceptions about the
potential for therapeutic efficacy (Gilbert,
2011).
However, there is disagreement in
the bioethics community as to whether,
in order to avoid therapeutic misconcep-
tion, patients must believe that only
future patients may derive benefits or
whether patients may believe that current
patients enrolled in the study may derive
benefits (Henderson et al., 2007). Sixteen
authors concurred on the following
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exists when individuals do not understand
that the defining purpose of clinical
research is to produce generalizable
knowledge, regardless of whether the
subject enrolled in the trial may potentially
benefit from the intervention under study
or from other aspects of the clinical trial.’’
The consensus definition suggests that
there is no therapeutic misconception
even if patients believe that they may
potentially benefit, so long as they under-
stand that the primary purpose of the trial
is to generate knowledge.
Onemust ask, then, if Geron’s informed
consent document for this study makes
clear the primary purpose. Is the research
intent clearly stipulated? The purpose of
the GRNOPC1 study is clearly stated in
the consent form as scientific research
rather than clinical benefit: ‘‘This study
will see if it is safe to inject GRNOPC1
into a person’s spinal cord..’’ Further,
the consent form begins with an acknowl-
edgment that GRNOPC1 is not approved
by the FDA, which clearly implies that it is
not accepted medical treatment. Later,
a very clear statement is made that ‘‘This
study is being conducted for research
purposes only.’’ Thus, the research intent
is clearly stipulated.
Are there statements that would lead
patients to believe that they are receiving
medical treatment? Only two statements
about benefits appear in the consent
form. The first reads: ‘‘GRNOPC1 has
not been given to human subjects prior
to this study, so it is not known if
GRNOPC1 will give any benefits to
humans with spinal cord injuries.’’ The
second statement, following five pages
of discussion of risks, simply reads:
‘‘The results from this study may help
the researchers understand the safety of
GRNOPC1.. It is unknown if there will
be any direct clinical benefit to you from
participating in this study.’’
In short, the GRNOPC1 informed
consent form for the study states the
research purpose clearly and makes no
claims that would lead patients to believe
that they are receiving medical treatment.
Statements made fit the guidelines
provided (Henderson et al., 2007) in cata-
loguing what must be done to avoid ther-
apeutic misconception.
Bretzner et al. suggest that even if
patients understand that they are not
receivingmedical treatment, theymay stillunderestimate the harms and overesti-
mate potential benefits, resulting in
a mistaken understanding of the benefit-
harm ratio. Such a misunderstanding
would make patients subject to possible
exploitation or ‘‘undue influence’’ in which
they are induced to agree to risks that are
not reasonable to undertake.
As noted above, only two statements in
Geron’s consent form make any claims
about benefits, and both of these suggest
that any benefits are ‘‘unknown.’’ Still,
there is the possibility that media hype
will lead any patient to presume that injec-
tion of stem cells has some therapeutic
potential. If so, then it becomes crucial
to know whether risks have been
adequately addressed and detailed.
Geron’s consent form devotes five full
pages to potential and even theoretical
risks: risks from the injection procedure,
from the GRNOPC1 cells, and from ancil-
lary testing procedures, such as blood
draws. Fluid leak at the injection site, the
formation of cystic tissue in the spinal
cord, immune rejection, possible mouse
viruses, increasing paralysis—all these
and many more risks are detailed. The
fact that long-term safety is not known is
also stressed: ‘‘There may be risks from
participating in this study that are
unknown, including allergic reactions,
which, if not treated promptly, could
become life-threatening. It is possible
that your condition may worsen.’’
Further, patients who would enter this
study go through 3 days of intensive and
careful screening and have opportunity
to ask questions and to withdraw at any
time during those days. Thus, while there
is never any guarantee that an individual
subject will not fall prey to underestimat-
ing harms and overestimating benefits,
the screening time aswell as care in state-
ments about risks and benefits reduces
this likelihood.
With a clear statement of research
intent, five pages of detailed review of
possible risks, and only two short state-
ments suggesting that it is ‘‘unknown’’
whether there will be any benefits, it is
hard see how patients could be ‘‘unduly
influenced’’ to underestimate the risks.
Only if the subjects are vulnerable in
a way that would render them unable to
absorb information and assess it reason-
ably could they be said to be particularly
at risk of therapeutic misconception.
Patients who for any reason cannotCell Stem Cunderstand and respond to the consent
form and process are excluded from the
trial.
Alternative Patient Populations
for the First Clinical Trial
SubjectswithChronic Complete SCI
Bretzner et al. recommend that the first
clinical trial with GRNOPC1 be conducted
in subjects with chronic complete SCI. As
noted in the paper (Keirstead et al., 2005)
cited by Bretzner et al., human embryonic
stem cell-derived oligodendrocyte
progenitor cells (GRNOPC1), did not yield
any enhanced remyelination or locomotor
recovery in rats when injected 10 months
after SCI. Thus, there is no preclinical data
to suggest even a theoretical possibility
that OPCs could have any efficacy what-
soever in humans with chronic SCI. In
contrast, the preclinical data do suggest
that OPCs might have efficacy in
subacute SCI. Given that the risks due to
GRNOPC1 injection, immunosuppres-
sion, and the GRNOPC1 cells (e.g.,
ectopic tissue formation) are similar for
both groups, the risk-to-benefit ratio
based on the preclinical data favors treat-
ment of patients with subacute SCI rather
than chronic SCI.
In addition, Bretzner et al. assert that
patients with chronic injuries have had
time to adjust to their life with paraplegia
‘‘which could help diminish the risk of
therapeutic misconception.’’ There is no
proof that these patients are less
‘‘desperate’’ for a cure than acute SCI
patients. After years of adaptation to
paralysis, they might be more aware of
the problems andmore eager for a change
in their circumstances than patients
recently diagnosed.
Subjects with Subacute Incomplete
Injuries
Bretzner et al. rightly point out that Phase
2 clinical studies are where efficacy of any
new therapeutic entity is more stringently
studied. The primary focus of the current
Phase 1 study, as stated above, is
the safety of GRNOPC1, not efficacy.
Subjects with subacute incomplete
injuries will likely be included in Phase 2
trials assuming safety is demonstrated in
Phase 1 trials. It should be noted,
however, that subjects with subacute
incomplete injuries are not the appro-
priate starting population for the
current first-in-human trial. Spontaneous
recovery is much greater in patients withell 8, May 6, 2011 ª2011 Elsevier Inc. 477
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reason that themany expert SCI clinicians
with whomGeron consulted during devel-
opment of the clinical protocol were unan-
imous in the opinion that the trial should
not begin with subacute incomplete SCI
patients. It is also for this reason that
similar previous trials (e.g., the ProNeuron
Phase 1 and 2 trials of autologous macro-
phages) restricted inclusion to subacute
complete SCI patients.
Subjects with Multiple Sclerosis
Bretzner et al. also indicate that patients
with progressive MS could be a candidate
patient population in which to study the
safety and efficacy of GRNOPC1. We
agree and hence are conducting preclin-
ical studies to examine the safety and effi-
cacy of GRNOPC1 in MS animal models.
Unfortunately, Bretzner et al. do not
provide compelling evidence to indicate
that this patient population is less vulner-478 Cell Stem Cell 8, May 6, 2011 ª2011 Elsable to therapeutic misconception than
subjects with subacute SCI and therefore
are better candidates for the first-in-
human trial.
Conclusion
In development of the first clinical trial
of GRNOPC1, numerous groups have
opined on the design of the trial and
content of the protocol along with the
informed consent form. These groups
include Geron’s clinical steering
committee, independent data monitoring
committee, embryonic stem cell research
oversight committee, investigators and
the FDA. In addition, 7 independent IRBs
and numerous other committees at the
clinical trial sites have reviewed and
approved the study. Multiple procedures
including stopping/suspension rules are
in place to mitigate risks to subjects in
the trial. Our goal is to execute thisevier Inc.trial with appropriate safeguards and
complete consideration of the subjects
in the trial.REFERENCES
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